...
首页> 外文期刊>Antimicrobial Resistance and Infection Control >Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis
【24h】

Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis

机译:耐药或多药耐药铜绿假单胞菌感染住院患者的危险因素:系统评价和荟萃分析

获取原文
           

摘要

Identifying risk factors predicting acquisition of resistant Pseudomonas aeruginosa will aid surveillance and diagnostic initiatives and can be crucial in early and appropriate antibiotic therapy.?We conducted a?systematic review examining risk factors of acquisition of resistant P. aeruginosa among hospitalized patients. MEDLINE?, EMBASE?, and Cochrane Central were searched between 2000 and 2016 for studies examining independent risk factors associated with acquisition of resistant P. aeruginosa, among hospitalized patients. Random effects model meta-analysis was conducted when at least three or more studies were sufficiently similar. Of the 54 eligible articles, 28 publications (31studies) examined multi-drug resistant (MDR) or extensively drug resistant (XDR) P. aeruginosa and 26 publications (29 studies) examined resistant P. aeruginosa. The acquisition of MDR P. aeruginosa, as compared with non-MDR P. aeruginosa, was significantly associated with intensive care unit (ICU) admission (3 studies: summary adjusted odds ratio [OR] 2.2) or use of quinolones (4 studies: summary adjusted OR 3.59). Acquisition of MDR or XDR compared with susceptible P. aeruginosa was significantly associated with prior hospital stay (4 studies: summary adjusted OR 1.90), use of quinolones (3 studies: summary adjusted OR 4.34), or use of carbapenems (3 studies: summary adjusted OR 13.68). The acquisition of MDR P. aeruginosa compared with non-P. aeruginosa was significantly associated with prior use of cephalosporins (3 studies: summary adjusted OR 3.96), quinolones (4 studies: summary adjusted OR 2.96), carbapenems (6 studies: summary adjusted OR 2.61), and prior hospital stay (4 studies: summary adjusted OR 1.74). The acquisition of carbapenem-resistant P. aeruginosa compared with susceptible P. aeruginosa, was statistically significantly associated with prior use of piperacillin-tazobactam (3 studies: summary adjusted OR 2.64), vancomycin (3 studies: summary adjusted OR 1.76), and carbapenems (7 studies: summary adjusted OR 4.36). Prior use of antibiotics and prior hospital or ICU stay was the most significant risk factors for acquisition of resistant P. aeruginosa. These findings provide guidance in identifying patients that may be at an elevated risk for a resistant infection and emphasize the importance of antimicrobial stewardship and infection control in hospitals.
机译:确定可预测获得耐药性铜绿假单胞菌的危险因素将有助于监测和诊断,在早期和适当的抗生素治疗中可能至关重要。我们进行了系统的审查,检查了住院患者中获得耐药性铜绿假单胞菌的危险因素。在2000年至2016年期间对MEDLINE ?、 EMBASE?和Cochrane Central进行了搜索,以研究在住院患者中与获得抗药性铜绿假单胞菌相关的独立危险因素。当至少三个或更多研究足够相似时,进行随机效应模型荟萃分析。在54篇合格文章中,有28篇出版物(31个研究)检查了多药耐药性(MDR)或广泛耐药性(XDR)铜绿假单胞菌,有26个出版物(29个研究)检查了耐药性铜绿假单胞菌。与非MDR铜绿假单胞菌相比,获得MDR铜绿假单胞菌与重症监护病房(ICU)的入院率显着相关(3项研究:汇总调整比值比[OR] 2.2)或使用喹诺酮(4项研究:摘要调整或3.59)。与易感性铜绿假单胞菌相比,MDR或XDR的获得与以前的住院时间(4项研究:汇总调整后为1.90),使用喹诺酮(3项研究:汇总调整后为4.34)或使用碳青霉烯(3项研究:汇总)显着相关调整为OR 13.68)。与非P相比,MDR铜绿假单胞菌的获得。铜绿假单胞菌与先前使用头孢菌素(3项研究:总结调整后的OR 3.96),喹诺酮类药物(4个研究:总结调整后的OR 2.96),碳青霉烯(6项研究:汇总调整后的OR 2.61)和先前的住院时间(4项研究:概要)调整后的OR 1.74)。与易感的铜绿假单胞菌相比,对碳青霉烯耐药的铜绿假单胞菌的获得与先前使用哌拉西林-他唑巴坦(3项研究:概述调整的OR 2.64),万古霉素(3项研究:概述调整的OR 1.76)和碳青霉烯显着相关(7个研究:摘要调整后的OR值为4.36)。先前使用抗生素和住院或重症监护病房是获得耐药铜绿假单胞菌的最重要危险因素。这些发现为确定耐药感染风险较高的患者提供了指导,并强调了抗菌素管理和感染控制在医院中的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号